



ASH 2021 abstracts:

What's hot in acute lymphoblastic leukemia?

To help navigate the exciting content being presented at the 63rd ASH Annual Meeting and Exposition, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.



Click
the abstracts
to view



Scientific Education Support

Top abstracts to look out for at ASH 2021

FRONTLINE THERAPIES

| | | |
|-----|--|--------------------|
| 215 | <u>Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol – a Graall Study</u> | Corentin Orvain |
| 362 | <u>First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)</u> | Nicola Gökbüget |
| 366 | <u>First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)</u> | Clare J Rowntree |
| 511 | <u>Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study</u> | Patrice Chevallier |
| 512 | <u>The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study</u> | Philippe Rousselot |

Top abstracts to look out for at ASH 2021

FRONTLINE THERAPIES continued

| | | |
|------|---|---------------------|
| 1232 | <u>Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2</u> | Nicolas Boissel |
| 1239 | <u>A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia</u> | Sangeetha Venugopal |
| 2298 | <u>Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</u> | Nicholas Short |
| 2300 | <u>Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)</u> | Matthias Stelljes |
| 3399 | <u>Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial</u> | Nicola Gökbüget |

TREATMENT FOR RELAPSED/REFRACTORY ALL

| | | |
|------|---|-------------------|
| 309 | <u>An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies</u> | Jorge Cortes |
| 363 | <u>A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331</u> | Patrick A. Brown |
| 428 | <u>Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry</u> | Samuel John |
| 473 | <u>High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)</u> | Peihua Lu |
| 516 | <u>Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis</u> | André Baruchel |
| 2299 | <u>A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia</u> | Nicholas J. Short |



EMERGING DIAGNOSTIC TOOLS

| | | |
|------|---|-------------------|
| 273 | <u>Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for the Genetic Characterization of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in Adults</u> | Claudia Haferlach |
| 274 | <u>Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia</u> | Thomas Gastinne |
| 3485 | <u>Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001</u> | Jonathan Paolino |

MECHANISMS OF TREATMENT RESISTANCE

| | | |
|-----|---|---------------------|
| 614 | <u>CD22^{low}/Bcl-2^{high} Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia</u> | Ernesto Diaz-Flores |
|-----|---|---------------------|

IMPACT OF COVID-19

| | | |
|-----|---|------------------|
| 216 | <u>ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report</u> | Sabina Chiaretti |
|-----|---|------------------|





Follow us on Twitter to keep up to date
with the latest from the 63rd ASH Annual
Meeting and Exposition!

@ALL_Hub_
#ASH2021
lymphoblastic-hub.com